These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 6333505)

  • 1. Development and evaluation of enteric-coated penicillamine tablets.
    Chambliss WG; Chambliss DA; Cleary RW; Jones AB; Harland EC; Kibbe AH
    J Pharm Sci; 1984 Sep; 73(9):1215-9. PubMed ID: 6333505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of enteric coating of aspirin tablets on occult gastrointestinal blood loss.
    Howe GB; Champion GD; Corrigan AB; Hewson J; Haski A; Day RO; Paull PD; Graham GG
    Aust N Z J Med; 1977 Dec; 7(6):600-4. PubMed ID: 350214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The permeability of enteric coatings and the dissolution rates of coated tablets.
    Porter SC; Ridgway K
    J Pharm Pharmacol; 1982 Jan; 34(1):5-8. PubMed ID: 6121034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets.
    Lui CY; Oberle R; Fleisher D; Amidon GL
    J Pharm Sci; 1986 May; 75(5):469-74. PubMed ID: 3735085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and stability evaluation of enteric coated Diclofenac sodium tablets using Sureteric.
    Zaid AN
    Pak J Pharm Sci; 2012 Jan; 25(1):59-64. PubMed ID: 22186310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an enteric coating formulation and process for tablets primarily composed of a highly water-soluble, organic acid.
    Crotts G; Sheth A; Twist J; Ghebre-Sellassie I
    Eur J Pharm Biopharm; 2001 Jan; 51(1):71-6. PubMed ID: 11154906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the absorption from some commercial enteric-release theophylline products.
    Upton RA; Powell JR; Guentert TW; Thiercelin JF; Sansom L; Coates PE; Riegelman S
    J Pharmacokinet Biopharm; 1980 Apr; 8(2):151-64. PubMed ID: 7431220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets.
    Pieniaszek HJ; Resetarits DE; Wilferth WW; Blumenthal HP; Bates TR
    J Clin Pharmacol; 1979 Jan; 19(1):39-45. PubMed ID: 33201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and evaluation of enteric-coated tablets for rifampicin and isoniazid combinations.
    Wang Y; Liu H; Liu K; Sun J; He Z
    Pharm Dev Technol; 2013; 18(2):401-6. PubMed ID: 22339279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of food and tablet formulation on plasma prednisolone levels following administration of enteric-coated tablets.
    Lee DA; Taylor GM; Walker JG; James VH
    Br J Clin Pharmacol; 1979 May; 7(5):523-8. PubMed ID: 475947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and IVIVC for mesalazine enteric-coated tablets.
    Zhang Y; Wo SK; Leng W; Gao F; Yan X; Zuo Z
    J Control Release; 2022 Jun; 346():275-288. PubMed ID: 35461968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy.
    Varum FJ; Hatton GB; Freire AC; Basit AW
    Eur J Pharm Biopharm; 2013 Aug; 84(3):573-7. PubMed ID: 23348235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enteric coated quinidine compared to sustained release preparations during repeated administration.
    Bakke OM; Aanderud L; Aslaksen A
    Acta Med Scand; 1980; 207(3):183-7. PubMed ID: 7368984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of fixed dose combination and physicochemical characterization of enteric-coated bilayer tablet with circadian rhythmic variations containing telmisartan and pravastatin sodium.
    Luo D; Kim JH; Park C; Oh E; Park JB; Cui JH; Cao QR; Lee BJ
    Int J Pharm; 2017 May; 523(1):343-356. PubMed ID: 28330645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug release from tablets containing cellulose acetate phthalate as an additive or enteric-coating material.
    Lin SY; Kawashima Y
    Pharm Res; 1987 Feb; 4(1):70-4. PubMed ID: 3508533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosage form design for improvement of bioavailability of levodopa VI: formulation of effervescent enteric-coated tablets.
    Nishimura K; Sasahara K; Arai M; Nitanai T; Ikegami Y; Morioka T; Nakajima E
    J Pharm Sci; 1984 Jul; 73(7):942-6. PubMed ID: 6088756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enteric-coated tablets improve oral bioavailability of DX-9065, a novel anticoagulant.
    Fujii Y; Kanamaru T; Kikuchi H; Yamashita S; Sakuma S
    Eur J Pharm Sci; 2011 Mar; 42(4):392-9. PubMed ID: 21238588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of omeprazole with enteric-coated salicylate tablets.
    Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leaky enteric coating on ranitidine hydrochloride beads: dissolution and prediction of plasma data.
    Bendas ER; Ayres JW
    Eur J Pharm Biopharm; 2008 Aug; 69(3):977-85. PubMed ID: 18424095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.